Alaunos Therapeutics Announces Registered Direct Offering

What Happened

• Alaunos Therapeutics, Inc. announced a registered direct offering that closed on September 21, 2026. The Company sold 380,469 shares of common stock at $1.46 per share and issued 386,654 pre‑funded warrants at $1.459 each. The offering was conducted under the Company’s effective Form S-3 registration statement and generated approximately $915,400.50 in net proceeds after estimated offering expenses and placement agent fees.

Key Details

• Offering structure: 380,469 common shares at $1.46 per share; 386,654 pre‑funded warrants at $1.459 per warrant.
• Net proceeds: approx. $915,400.50 after expenses (including placement agent fees).
• Placement agent: Dawson James Securities, Inc.; cash fee paid to agent equal to 8% of gross proceeds plus expense reimbursement.
• Pre‑funded warrants: exercisable immediately for $0.001 per share, do not expire, may be exercised for cash or cashless if no effective registration statement; subject to a beneficial ownership cap of 4.99% (can be elected up to 9.99% with 60 days’ notice).
• Insider lock-up: Company officers and directors agreed to a 15‑day lock-up following the offering.

Why It Matters

• This is a small-cap financing that provides immediate working capital and general corporate funds for Alaunos. The pre‑funded warrants were used to limit any single investor’s post‑offering ownership above the 4.99% threshold, reducing the need for larger share issuances now but creating potential future dilution if warrants are exercised. Investors should note the modest size of the raise, the warrant terms (very low exercise price but ownership caps), and the placement agent fee (8%), all of which affect dilution and net funds available.